A Phase 3 interventional study of LAMICTAL extended-release in Epilepsy and Epilepsy, Partial, sponsored by GlaxoSmithKline. Completed at 148 sites in 10 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2016-12-05.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.
Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 24th largest by enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2004, is one of 31 in phase 3, and was the 10th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 34 · Phase 4 9
First in 1992; this study’s year is marked. 6 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 86 interventional studies, 100 across the 16 observational. Of the 73 that completed or were terminated, 37 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 102 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 7 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Partial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07505004Phase 3Praxis Precision MedicinesRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | 2027-01 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT05673915Mayo ClinicStudy of Transcranial Direct Current Stimulation to Treat Epilepsy | 2026-12 |
| NCT05794295University of California, DavisSleep Architecture & Cognition in Focal Epilepsy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies in Epilepsies, Partial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
This study's enrollment of 244 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Browse Epilepsies, Partial studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The efficacy of LAMICTAL extended-release therapy will be measured by the percentage change from Baseline in partial seizure frequency during the double-blind treatment phase.
Time frame: 24 Weeks
Reduction in partial seizure frequency during portions of double-blind phase (=25%,=50%,=75%,100%). Time to 50% reduction in partial seizure frequency. Adverse events. Weight change. Health outcomes questionnaires. Population Pharmacokinetics
Time frame: 24 Weeks
Showing the first 100 of 148 sites across 10 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Oct 2004, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine